Evidence map›Paper›PMID 26763166›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2016

Enhanced and Differential Capture of Circulating Tumor Cells from Lung Cancer Patients by Microfluidic Assays Using Aptamer Cocktail.

Libo Zhao, Chuanhao Tang, Li Xu, Zhen Zhang, Xiaoyan Li, Haixu Hu, Si Cheng, Wei Zhou, Mengfei Huang, Anna Fong and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Advances in Oligonucleotide Aptamers for NSCLC Targeting.International journal of molecular sciences · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Libo ZhaoBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Chuanhao TangDepartment of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Li XuBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Zhen ZhangBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Xiaoyan LiDepartment of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Haixu HuLaboratory of Oncology, Translational Medicine Center, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Si ChengBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Wei ZhouBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Mengfei HuangBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.
Anna FongDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Bing LiuLaboratory of Oncology, Translational Medicine Center, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Hongjun GaoDepartment of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Yi LiuLaboratory of Oncology, Translational Medicine Center, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, P. R. China.
Xiaohong FangBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry Chinese Academy of Sciences, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China.

Funding

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
CTC Purification System Based on Thermoresponsive NanoSubstratesR44CA180482 · NCI · CYTOLUMINA TECHNOLOGIES CORPORATION, INC · PI LIU, SEAN XIAO, TSENG, HSIAN-RONG · 2015 to 2016
$2.0M
NCI NIH HHS R44 CA180482NCI NIH HHS U01 CA198900
6 · The paper itself

Abstract

Collecting circulating tumor cells (CTCs) shed from solid tumor through a minimally invasive approach provides an opportunity to solve a long-standing oncology problem, the real-time monitoring of tumor state and analysis of tumor heterogeneity. However, efficient capture and detection of CTCs with diverse phenotypes is still challenging. In this work, a microfluidic assay is developed using the rationally-designed aptamer cocktails with synergistic effect. Enhanced and differential capture of CTCs for nonsmall cell lung cancer (NSCLC) patients is achieved. It is also demonstrated that the overall consideration of CTC counts obtained by multiple aptamer combinations can provide more comprehensive information in treatment monitoring.

Indexed as

Aptamers, NucleotideCell Line, TumorFluorescenceHumansLung NeoplasmsMicrofluidicsNanowiresNeoplastic Cells, CirculatingReproducibility of ResultsSiliconAptamers, NucleotideSiliconaptamerscancer diagnosiscirculating tumor cellsrare cell enrichmenttumor heterogeneity

Identifiers

PMID26763166
PMCPMC4893320

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.